Aratana Therapeutics Inc (NASDAQ:PETX) shares were falling nearly 18% on the heels of Friday’s announcement revealing that Entyce, approved in the U.S.
Aratana Therapeutics Inc (NASDAQ:PETX) investors are wildly disappointed today after the pet medicine maker provided a corporate update as follows: The Company now anticipates that …
Post-operative pain drug Nocita expected to begin generating widespread sales, says William Blair
Credit Suisse analyst Erin Wilson weighed in on Aratana Therapeutics (NASDAQ:PETX), after the pet biopharmaceutical company reported second-quarter results, posting EPS of ($0.48), below Wilson’s projection of ($0.
Global X Funds (NYSEARCA:GREK) plummeted -17% in pre-market trading to $9.75 after the European Central bank announced it would not expand Greece’s emergency …
In a research report issued today, William Blair analyst John Kreger assigned an Outperform rating on Aratana Therapeutics (NASDAQ:PETX), following the company’s public …
In a research report issued yesterday, William Blair analyst John Kreger maintained an Outperform rating on Aratana Therapeutics (NASDAQ:PETX), following yesterday’s news that …
